

Nikolai Petrovsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3152191/publications.pdf>

Version: 2024-02-01

299
papers

23,409
citations

23567

58
h-index

8866

145
g-index

318
all docs

318
docs citations

318
times ranked

27356
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined delivery of TLR2 and TLR7 agonists by Nanostructured lipid carriers induces potent vaccine adjuvant activity in mice. <i>International Journal of Pharmaceutics</i> , 2022, 613, 121378.	5.2	6
2	An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission. <i>Npj Vaccines</i> , 2022, 7, 24.	6.0	18
3	Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model. <i>Frontiers in Immunology</i> , 2022, 13, 828690.	4.8	5
4	A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model. <i>Npj Vaccines</i> , 2022, 7, 34.	6.0	5
5	A Spike Protein-Based Subunit SARS-CoV-2 Vaccine for Pets: Safety, Immunogenicity, and Protective Efficacy in Juvenile Cats. <i>Frontiers in Veterinary Science</i> , 2022, 9, 815978.	2.2	12
6	Safety and immunogenicity of SpikoGen [®] , an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1263-1271.	6.0	37
7	Covax-19/Spikogen [®] vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters. <i>Vaccine</i> , 2022, 40, 3182-3192.	3.8	25
8	Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice. <i>Microorganisms</i> , 2022, 10, 1034.	3.6	1
9	Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine <i>Onchocerca ochengi</i> Infection Model of Human Onchocerciasis. <i>Vaccines</i> , 2022, 10, 861.	4.4	5
10	A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates. <i>Vaccine</i> , 2022, 40, 4625-4634.	3.8	4
11	Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7704.	4.1	5
12	Immunogenicity and safety of SpikoGen [®] , an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial. <i>Immunology</i> , 2022, 167, 340-353.	4.4	26
13	Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. <i>Current Opinion in Chemical Biology</i> , 2022, 70, 102172.	6.1	40
14	Developing Translational Vaccines against Heroin and Fentanyl through Investigation of Adjuvants and Stability. <i>Molecular Pharmaceutics</i> , 2021, 18, 228-235.	4.6	11
15	TLR2 Agonistic Small Molecules: Detailed Structure-Activity Relationship, Applications, and Future Prospects. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 233-278.	6.4	26
16	An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein. <i>Npj Vaccines</i> , 2021, 6, 13.	6.0	34
17	Strategies for active and passive pediatric RSV immunization. , 2021, 9, 251513552098151.	2.3	13
18	Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1065-1120.	3.9	15

#	ARTICLE	IF	CITATIONS
19	Intrapulmonary vaccination with delta-inulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction. <i>Mucosal Immunology</i> , 2021, 14, 762-773.	6.0	8
20	Human plasmacytoid dendritic cells at the crossroad of type I interferon-regulated B cell differentiation and antiviral response to tick-borne encephalitis virus. <i>PLoS Pathogens</i> , 2021, 17, e1009505.	4.7	6
21	Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets. <i>Npj Vaccines</i> , 2021, 6, 59.	6.0	9
22	Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity. <i>Vaccine</i> , 2021, 39, 1990-1996.	3.8	4
23	Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines. <i>Pathogens</i> , 2021, 10, 500.	2.8	11
24	Toll-like receptor-7/8 agonist kill <i>Leishmania amazonensis</i> by acting as pro-oxidant and pro-inflammatory agent. <i>Journal of Pharmacy and Pharmacology</i> , 2021, 73, 1180-1190.	2.4	5
25	Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice. <i>Pathogens</i> , 2021, 10, 626.	2.8	7
26	In Vitro Characterization of the Innate Immune Pathways Engaged by Live and Inactivated Tick-Borne Encephalitis Virus. <i>Vaccines</i> , 2021, 9, 664.	4.4	3
27	In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. <i>Scientific Reports</i> , 2021, 11, 13063.	3.3	77
28	Impaired Ca ²⁺ signaling due to hepatic steatosis mediates hepatic insulin resistance in Alström syndrome mice that is reversed by GLP-1 analog treatment. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 321, C187-C198.	4.6	5
29	A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization. <i>Vaccine</i> , 2021, 39, 5162-5172.	3.8	9
30	Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection. <i>MBio</i> , 2021, 12, e0201821.	4.1	5
31	Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. <i>Vaccine</i> , 2021, 39, 5940-5953.	3.8	44
32	Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies. <i>Molecular Biomedicine</i> , 2021, 2, 28.	4.4	10
33	A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection. <i>Vaccine</i> , 2021, 39, 5866-5875.	3.8	9
34	Lethal Human Coronavirus Infections and the Role of Vaccines in Their Prevention. , 2021, , 533-549.		1
35	Onchocerca volvulus bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice. <i>Npj Vaccines</i> , 2021, 6, 17.	6.0	11
36	Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance. <i>Diabetes</i> , 2021, 70, 364-376.	0.6	23

#	ARTICLE	IF	CITATIONS
37	An Advax-Adjuvanted Inactivated Cell-Culture Derived Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-Flavivirus Antibodies, Robust Cellular Immunity and Provides Single Dose Protection. <i>Vaccines</i> , 2021, 9, 1235.	4.4	5
38	Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. <i>Bioanalysis</i> , 2021, 13, 1805-1826.	1.5	11
39	In vitro assessment of tick-borne encephalitis vaccine: Suitable human cell platforms and potential biomarkers. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2021, 38, 431-441.	1.5	1
40	Flavivirus DNA Vaccine Design and Adjuvant Selection. <i>Methods in Molecular Biology</i> , 2021, 2183, 405-422.	0.9	1
41	Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates. <i>Vaccine</i> , 2021, 39, 7446-7456.	3.8	9
42	Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology. <i>Neurobiology of Disease</i> , 2020, 134, 104636.	4.4	15
43	Characterization of humoral immune responses and degree of protection induced by influenza vaccine in cotton rats: Effects of low vaccine dose and single vs booster vaccination. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 279-291.	2.7	2
44	Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection. <i>Frontiers in Immunology</i> , 2020, 11, 1673.	4.8	39
45	Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity. <i>Vaccine</i> , 2020, 38, 7885-7891.	3.8	9
46	Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis. <i>Npj Vaccines</i> , 2020, 5, 105.	6.0	45
47	Vaccine-Induced Th1-Type Response Protects against Invasive Group A <i>Streptococcus</i> Infection in the Absence of Opsonizing Antibodies. <i>MBio</i> , 2020, 11, .	4.1	33
48	Adjuvant selection impacts the correlates of vaccine protection against Ebola infection. <i>Vaccine</i> , 2020, 38, 4601-4608.	3.8	10
49	Influence of Oxidation Degree on the Physicochemical Properties of Oxidized Inulin. <i>Polymers</i> , 2020, 12, 1025.	4.5	11
50	Comparison of influenza-specific neutralizing antibody titers determined using different assay readouts and hemagglutination inhibition titers: good correlation but poor agreement. <i>Vaccine</i> , 2020, 38, 2527-2541.	3.8	17
51	BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1989-1996.	3.3	10
52	Rational Structure-Based Drug Design. , 2019, , 585-600.		3
53	Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. <i>Microorganisms</i> , 2019, 7, 255.	3.6	28
54	Neonatal vaccine effectiveness and the role of adjuvants. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 869-878.	3.0	12

#	ARTICLE	IF	CITATIONS
55	Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 504-513.e16.	2.9	17
56	A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice. <i>Scientific Reports</i> , 2019, 9, 15455.	3.3	18
57	Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery. <i>Pharmaceutics</i> , 2019, 11, 555.	4.5	16
58	Doxorubicin-Loaded Delta Inulin Conjugates for Controlled and Targeted Drug Delivery: Development, Characterization, and In Vitro Evaluation. <i>Pharmaceutics</i> , 2019, 11, 581.	4.5	20
59	Enhanced Antiviral Activity of Human Surfactant Protein D by Site-Specific Engineering of the Carbohydrate Recognition Domain. <i>Frontiers in Immunology</i> , 2019, 10, 2476.	4.8	10
60	MicroRNA-Related Genetic Variants Are Associated With Diabetic Retinopathy in Type 1 Diabetes Mellitus. , 2019, 60, 3937.		11
61	Mitochondrial haplogroups are not associated with diabetic retinopathy in a large Australian and British Caucasian sample. <i>Scientific Reports</i> , 2019, 9, 612.	3.3	2
62	Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes. <i>Pharmaceutics</i> , 2019, 11, 243.	4.5	10
63	Review of polysaccharide particle-based functional drug delivery. <i>Carbohydrate Polymers</i> , 2019, 221, 94-112.	10.2	240
64	Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization. <i>Frontiers in Immunology</i> , 2019, 10, 646.	4.8	14
65	Calcium Signaling As a Therapeutic Target for Liver Steatosis. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 270-281.	7.1	30
66	Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas. <i>Viruses</i> , 2019, 11, 212.	3.3	75
67	A Microfluidic Tumor-on-a-Chip for Assessing Multifunctional Liposomes' Tumor Targeting and Anticancer Efficacy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1900015.	7.6	47
68	Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 172, 1-8.	2.8	7
69	Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production. <i>Vaccine</i> , 2019, 37, 1630-1637.	3.8	40
70	Prediction of novel mouse $\hat{A}TLR9$ agonists using a random forest approach. <i>BMC Molecular and Cell Biology</i> , 2019, 20, 56.	2.0	5
71	Testing a MultiTEP-based combination vaccine to reduce $A\beta^2$ and tau pathology in Tau22/5xFAD bigenic mice. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 107.	6.2	19
72	Microfluidic formation of core-shell alginate microparticles for protein encapsulation and controlled release. <i>Journal of Colloid and Interface Science</i> , 2019, 539, 497-503.	9.4	102

#	ARTICLE	IF	CITATIONS
73	Synthesis and characterization of a novel inulin hydrogel crosslinked with pyromellitic dianhydride. <i>Reactive and Functional Polymers</i> , 2019, 134, 104-111.	4.1	42
74	Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus. <i>Drug Delivery</i> , 2018, 25, 533-545.	5.7	25
75	Monophosphoryl Lipid A-Adjuvanted Virosomes with Ni-Chelating Lipids for Attachment of Conserved Viral Proteins as Cross-Protective Influenza Vaccine. <i>Biotechnology Journal</i> , 2018, 13, e1700645.	3.5	20
76	A novel peptide-based vaccine candidate with protective efficacy against influenza A in a mouse model. <i>Virology</i> , 2018, 515, 21-28.	2.4	33
77	The Safety of an Adjuvanted Autologous Cancer Vaccine Platform in Canine Cancer Patients. <i>Veterinary Sciences</i> , 2018, 5, 87.	1.7	5
78	Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines. <i>Frontiers in Immunology</i> , 2018, 9, 2312.	4.8	22
79	Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 133, 85-95.	4.3	18
80	Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. <i>Journal of Controlled Release</i> , 2018, 288, 199-211.	9.9	43
81	Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy. <i>BMC Medical Genetics</i> , 2018, 19, 71.	2.1	49
82	Effector mechanisms of influenza-specific antibodies: neutralization and beyond. <i>Expert Review of Vaccines</i> , 2018, 17, 785-795.	4.4	33
83	Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1261-1271.	3.3	5
84	X-ray crystal structure of rivoglitazone bound to PPAR β and PPAR subtype selectivity of TZDs. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 1981-1991.	2.4	15
85	Multistage vaccines containing outer membrane, type III secretion system and inclusion membrane proteins protects against a Chlamydia genital tract infection and pathology. <i>Vaccine</i> , 2017, 35, 3883-3888.	3.8	18
86	Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines. <i>EBioMedicine</i> , 2017, 15, 127-136.	6.1	39
87	Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against <i>Mycobacterium tuberculosis</i> infection. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2967-2976.	3.3	10
88	Proteomic analysis of influenza haemagglutinin-specific antibodies following vaccination reveals convergent immunoglobulin variable region signatures. <i>Vaccine</i> , 2017, 35, 5576-5580.	3.8	9
89	Investigation of the biodistribution, breakdown and excretion of delta inulin adjuvant. <i>Vaccine</i> , 2017, 35, 4382-4388.	3.8	17
90	Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial. <i>BMC Infectious Diseases</i> , 2017, 17, 241.	2.9	30

#	ARTICLE	IF	CITATIONS
91	Vaccine Adjuvant Nanotechnologies. , 2017, , 127-147.		7
92	Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation. Vaccines, 2017, 5, 19.	4.4	4
93	Distinctive Responses in an In Vitro Human Dendritic Cell-Based System upon Stimulation with Different Influenza Vaccine Formulations. Vaccines, 2017, 5, 21.	4.4	21
94	Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats. PLoS ONE, 2017, 12, e0186484.	2.5	16
95	Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection. Scientific Reports, 2017, 7, 8582.	3.3	57
96	DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. Journal of General Virology, 2017, 98, 2143-2155.	2.9	9
97	Molecular Adjuvants for DNA Vaccines. Current Issues in Molecular Biology, 2017, 22, 17-40.	2.4	49
98	Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology. Human Vaccines and Immunotherapeutics, 2016, 12, 2096-2105.	3.3	21
99	Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant. Methods in Molecular Biology, 2016, 1403, 269-284.	0.9	24
100	Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax, delta inulin adjuvant. Vaccine, 2016, 34, 3780-3786.	3.8	49
101	Influenza immunization during pregnancy: Benefits for mother and infant. Human Vaccines and Immunotherapeutics, 2016, 12, 3065-3071.	3.3	54
102	Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens. Antiviral Research, 2016, 133, 14-22.	4.1	18
103	Alzheimer's disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A β pathological molecules. Scientific Reports, 2016, 6, 28912.	3.3	37
104	Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project. Vaccine, 2016, 34, 5845-5854.	3.8	9
105	Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes. Nature Genetics, 2016, 48, 519-527.	21.4	117
106	Promoter polymorphism at the tumour necrosis factor/lymphotoxin-alpha locus is associated with type of diabetes but not with susceptibility to sight-threatening diabetic retinopathy. Diabetes and Vascular Disease Research, 2016, 13, 164-167.	2.0	7
107	A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. Acta Diabetologica, 2016, 53, 643-650.	2.5	53
108	Physical characterization and in silico modeling of inulin polymer conformation during vaccine adjuvant particle formation. Carbohydrate Polymers, 2016, 143, 108-115.	10.2	33

#	ARTICLE	IF	CITATIONS
109	Molecular mechanisms for enhanced DNA vaccine immunogenicity. <i>Expert Review of Vaccines</i> , 2016, 15, 313-329.	4.4	231
110	Safety and tolerability evaluation of the use of Montanide ISA [®] 51 as vaccine adjuvant: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 159-169.	3.3	99
111	Dengue tropism for macrophages and dendritic cells: the host cell effect. <i>Journal of General Virology</i> , 2016, 97, 1531-1536.	2.9	25
112	The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against <i>Onchocerca volvulus</i> in Mice. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004797.	3.0	20
113	Innate Responses Induced by Whole Inactivated Virus or Subunit Influenza Vaccines in Cultured Dendritic Cells Correlate with Immune Responses In Vivo. <i>PLoS ONE</i> , 2015, 10, e0125228.	2.5	20
114	Identification and characterisation of T-cell epitopes for incorporation into dendritic cell-delivered <i>Listeria</i> vaccines. <i>Journal of Immunological Methods</i> , 2015, 424, 111-119.	1.4	20
115	A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax [®] delta inulin adjuvant induces robust T-cell protection against listeria infection. <i>Vaccine</i> , 2015, 33, 1465-1473.	3.8	77
116	A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1246-1259.	0.8	50
117	Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection. <i>Vaccine</i> , 2015, 33, 4892-4900.	3.8	43
118	Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema. <i>Ophthalmology</i> , 2015, 122, 1828-1836.	5.2	20
119	Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 231-241.	4.3	16
120	Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology. <i>Journal of Virology</i> , 2015, 89, 2995-3007.	3.4	186
121	Advax [®] delta, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. <i>Vaccine</i> , 2015, 33, 5920-5926.	3.8	95
122	Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. <i>Diabetologia</i> , 2015, 58, 2288-2297.	6.3	73
123	Novel nanoparticle vaccines for Listeriosis. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2501-2503.	3.3	19
124	Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. <i>Drug Safety</i> , 2015, 38, 1059-1074.	3.2	238
125	Inulin crystal initiation via a glucose-fructose cross-link of adjacent polymer chains: Atomic force microscopy and static molecular modelling. <i>Carbohydrate Polymers</i> , 2015, 117, 964-972.	10.2	23
126	Enhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 66, 118-122.	4.0	18

#	ARTICLE	IF	CITATIONS
127	Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine. PLoS ONE, 2015, 10, e0132003.	2.5	21
128	Characterisation of adjuvants for use in dromedary immunisation. Journal of Camel Practice and Research, 2015, 22, 33.	0.1	0
129	In Silico Structural Homology Modelling and Docking for Assessment of Pandemic Potential of a Novel H7N9 Influenza Virus and Its Ability to Be Neutralized by Existing Anti-Hemagglutinin Antibodies. PLoS ONE, 2014, 9, e102618.	2.5	10
130	Editorial (Thematic Issue: The Coming of Age of DNA Vaccines). Current Gene Therapy, 2014, 14, 147-148.	2.0	1
131	Advax-Adjuvanted Recombinant Protective Antigen Provides Protection against Inhalational Anthrax That Is Further Enhanced by Addition of Murabutide Adjuvant. Vaccine Journal, 2014, 21, 580-586.	3.1	49
132	Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals. Veterinary Research, 2014, 45, 130.	3.0	32
133	Sugar-Based Immune Adjuvants for Use in Recombinant, Viral Vector, DNA and Other Styles of Vaccines. , 2014, , 179-200.		0
134	Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. Journal of Controlled Release, 2014, 174, 51-62.	9.9	44
135	Gamma ray sterilization of delta inulin adjuvant particles (Advax [®] , [®]) makes minor, partly reversible structural changes without affecting adjuvant activity. Vaccine, 2014, 32, 552-557.	3.8	7
136	Genetic study of diabetic retinopathy: recruitment methodology and analysis of baseline characteristics. Clinical and Experimental Ophthalmology, 2014, 42, 486-493.	2.6	14
137	Immunogenicity and safety of Advax [®] , [®] , a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study. Vaccine, 2014, 32, 6469-6477.	3.8	81
138	Pulmonary immunization of chickens using non-adjuvanted spray-freeze dried whole inactivated virus vaccine completely protects against highly pathogenic H5N1 avian influenza virus. Vaccine, 2014, 32, 6445-6450.	3.8	12
139	A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax [®] , [®]) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection. Vaccine, 2014, 32, 4651-4659.	3.8	38
140	Inulin isoforms differ by repeated additions of one crystal unit cell. Carbohydrate Polymers, 2014, 103, 392-397.	10.2	19
141	Plasmids Encoding Protein Aggregation Domains Act As Molecular Adjuvants for DNA Vaccines. Current Gene Therapy, 2014, 14, 161-169.	2.0	6
142	Vaccine adjuvants: in search of new paradigms. Expert Review of Vaccines, 2013, 12, 723-726.	4.4	5
143	Computational vaccinology and the ICoVax 2012 workshop. BMC Bioinformatics, 2013, 14, 11.	2.6	10
144	Vaccine adjuvant safety: the elephant in the room. Expert Review of Vaccines, 2013, 12, 715-717.	4.4	15

#	ARTICLE	IF	CITATIONS
145	A randomized controlled study to assess the immunogenicity and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a disposable syringe jet injector device versus a traditional pre-filled syringe and needle. <i>Trials in Vaccinology</i> , 2013, 2, 39-44.	1.2	9
146	Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: Comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 716-725.	4.3	33
147	The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions. <i>Glycobiology</i> , 2013, 23, 1164-1174.	2.5	45
148	A novel hepatitis B vaccine containing Advax [®] , a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. <i>Vaccine</i> , 2013, 31, 1999-2007.	3.8	125
149	JE-ADVAX Vaccine Protection against Japanese Encephalitis Virus Mediated by Memory B Cells in the Absence of CD8 ⁺ T Cells and Pre-Exposure Neutralizing Antibody. <i>Journal of Virology</i> , 2013, 87, 4395-4402.	3.4	46
150	Flu watch. <i>New Scientist</i> , 2013, 218, 34.	0.0	0
151	Chiral Self-Assembly of Designed Amphiphiles: Influences on Aggregate Morphology. <i>Langmuir</i> , 2013, 29, 10001-10010.	3.5	17
152	An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody. <i>Journal of Virology</i> , 2013, 87, 10324-10333.	3.4	73
153	Immunotherapy – 2076. A controlled study of delta inulin-adjuvanted honey bee venom immunotherapy. <i>World Allergy Organization Journal</i> , 2013, 6, P158.	3.5	16
154	Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies. <i>PLoS ONE</i> , 2013, 8, e69649.	2.5	15
155	Unconventional Vaccines: Progress and Challenges. <i>Journal of Vaccines & Vaccination</i> , 2013, 04, .	0.3	1
156	Systems Immunology, Vaccine Adjuvant. , 2013, , 2092-2094.		0
157	Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment. <i>Diabetes Care</i> , 2012, 35, 218-225.	8.6	108
158	Report from the field. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1006-1009.	3.3	2
159	The future of human DNA vaccines. <i>Journal of Biotechnology</i> , 2012, 162, 171-182.	3.8	165
160	Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax [®] , polysaccharide adjuvant. <i>Vaccine</i> , 2012, 30, 5407-5416.	3.8	98
161	Advax [®] , a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. <i>Vaccine</i> , 2012, 30, 5373-5381.	3.8	144
162	BBS-Induced Ciliary Defect Enhances Adipogenesis, Causing Paradoxical Higher-Insulin Sensitivity, Glucose Usage, and Decreased Inflammatory Response. <i>Cell Metabolism</i> , 2012, 16, 363-377.	16.2	75

#	ARTICLE	IF	CITATIONS
163	Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. <i>Expert Review of Vaccines</i> , 2012, 11, 1459-1470.	4.4	29
164	Technologies for enhanced efficacy of DNA vaccines. <i>Expert Review of Vaccines</i> , 2012, 11, 189-209.	4.4	265
165	Observation of the keto tautomer of d-fructose in D2O using 1H NMR spectroscopy. <i>Carbohydrate Research</i> , 2012, 347, 136-141.	2.3	132
166	Analysis of the hydrolysis of inulin using real time 1H NMR spectroscopy. <i>Carbohydrate Research</i> , 2012, 352, 117-125.	2.3	68
167	Towards tailored vaccine delivery: Needs, challenges and perspectives. <i>Journal of Controlled Release</i> , 2012, 161, 363-376.	9.9	93
168	Relationship between DDAH gene variants and serum ADMA level in individuals with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2012, 26, 195-198.	2.3	11
169	Induction of Heterosubtypic Cross-Protection against Influenza by a Whole Inactivated Virus Vaccine: The Role of Viral Membrane Fusion Activity. <i>PLoS ONE</i> , 2012, 7, e30898.	2.5	79
170	Enhancement of the Immunogenicity and Protective Efficacy of a Mucosal Influenza Subunit Vaccine by the Saponin Adjuvant GPI-0100. <i>PLoS ONE</i> , 2012, 7, e52135.	2.5	35
171	Alström syndrome: insights into the pathogenesis of metabolic disorders. <i>Nature Reviews Endocrinology</i> , 2011, 7, 77-88.	9.6	88
172	Carbohydrate-based immune adjuvants. <i>Expert Review of Vaccines</i> , 2011, 10, 523-537.	4.4	133
173	Pediatric influenza immunization. <i>Expert Review of Vaccines</i> , 2011, 10, 567-570.	4.4	2
174	Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. <i>Vaccine</i> , 2011, 29, 4345-4352.	3.8	75
175	Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. <i>Vaccine</i> , 2011, 29, 6242-6251.	3.8	58
176	Dyspnea in Pulmonary Arterial Hypertension. , 2011, , .		0
177	Effects of perindoprilâ€“indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy. <i>Journal of Hypertension</i> , 2011, 29, 1439-1447.	0.5	20
178	Serological responses following influenza A H1N1 2009 infection in adults. <i>Journal of Infection</i> , 2011, 62, 388-393.	3.3	12
179	Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. <i>Journal of General Virology</i> , 2011, 92, 128-140.	2.9	69
180	Challenges in improving influenza vaccine protection in the elderly. <i>Expert Review of Vaccines</i> , 2011, 10, 7-11.	4.4	4

#	ARTICLE	IF	CITATIONS
181	Delta inulin: a novel, immunologically active, stable packing structure comprising α -D-[2 \rightarrow 1] poly(fructo-furanosyl) α -D-glucose polymers. <i>Glycobiology</i> , 2011, 21, 595-606.	2.5	110
182	World Vaccine Congress Asia 2011 (June 20-24, 2011, Singapore). <i>Drugs of the Future</i> , 2011, 36, 801.	0.1	0
183	Immunome Research-Five Years On. <i>Immunome Research</i> , 2011, 7, .	0.1	0
184	Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant. <i>AAPS Journal</i> , 2010, 12, 109-116.	4.4	58
185	Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures. <i>AAPS Journal</i> , 2010, 12, 215-222.	4.4	53
186	Sequence Variation in DDAH1 and DDAH2 Genes Is Strongly and Additively Associated with Serum ADMA Concentrations in Individuals with Type 2 Diabetes. <i>PLoS ONE</i> , 2010, 5, e9462.	2.5	54
187	An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. <i>Journal of General Virology</i> , 2010, 91, 1407-1417.	2.9	88
188	Management of dyspnea in advanced pulmonary arterial hypertension. <i>Current Opinion in Supportive and Palliative Care</i> , 2010, 4, 76-84.	1.3	15
189	Aldose Reductase Gene Polymorphisms and Diabetic Retinopathy Susceptibility. <i>Diabetes Care</i> , 2010, 33, 1834-1836.	8.6	39
190	Association Between Erythropoietin Gene Polymorphisms and Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2010, 128, 102.	2.4	51
191	Needle-free influenza vaccination. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 699-711.	9.1	105
192	Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2010, 6, 131-138.	9.6	27
193	Diabetic Retinopathy Is Associated With Elevated Serum Asymmetric and Symmetric Dimethylarginines. <i>Diabetes Care</i> , 2009, 32, 2084-2086.	8.6	53
194	Common Sequence Variation in the VEGFA Gene Predicts Risk of Diabetic Retinopathy. , 2009, 50, 5552.		64
195	The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. <i>Nature Genetics</i> , 2009, 41, 553-562.	21.4	408
196	AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against <i>Plasmodium falciparum</i> merozoite surface protein 4 and 5. <i>Malaria Journal</i> , 2009, 8, 35.	2.3	13
197	P11-21. Induction of persistent mucosal humoral and cellular responses following immunization of mice with HIV-1 envelope protein in inulin-derived adjuvants. <i>Retrovirology</i> , 2009, 6, .	2.0	0
198	Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. <i>Influenza and Other Respiratory Viruses</i> , 2008, 2, 41-51.	3.4	82

#	ARTICLE	IF	CITATIONS
199	Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial*. Diabetes, Obesity and Metabolism, 2008, 10, 387-399.	4.4	60
200	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2008, 358, 2560-2572.	27.0	6,447
201	Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine, 2008, 26, 2350-2359.	3.8	125
202	4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor β agonist alleviates the symptoms of DSS-induced colitis. Biochemical and Biophysical Research Communications, 2008, 367, 566-572.	2.1	13
203	Freeing vaccine adjuvants from dangerous immunological dogma. Expert Review of Vaccines, 2008, 7, 7-10.	4.4	59
204	Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling. PLoS Pathogens, 2008, 4, e1000138.	4.7	221
205	The Future for Computational Modelling and Prediction Systems in Clinical Immunology. Novartis Foundation Symposium, 2008, , 23-42.	1.1	9
206	Immunoinformatics-The New Kid in Town. Novartis Foundation Symposium, 2008, , 3-22.	1.1	22
207	Cellular Delivery of siRNA Mediated by Fusion-Active Virosomes. Journal of Liposome Research, 2007, 17, 39-47.	3.3	24
208	Bioinformatics for study of autoimmunity. Autoimmunity, 2006, 39, 635-643.	2.6	20
209	Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochemical and Biophysical Research Communications, 2006, 342, 1152-1159.	2.1	112
210	Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine, 2006, 24, S26-S29.	3.8	71
211	PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing. Immunome Research, 2006, 2, 3.	0.1	62
212	Fat Aussie – A New Alstroÿm Syndrome Mouse Showing a Critical Role for ALMS1 in Obesity, Diabetes, and Spermatogenesis. Molecular Endocrinology, 2006, 20, 1610-1622.	3.7	147
213	PREDNOD, a prediction server for peptide binding to the H-2g7haplotype of the non-obese diabetic mouse. Autoimmunity, 2006, 39, 645-650.	2.6	5
214	Data Extraction for Improved Prediction Outcomes in Organ Transplantation – A Hybrid Approach. , 2006, , .		0
215	Hypothyroidism and hyponatraemia in the hospital setting. Pathology, 2005, 37, 179-181.	0.6	5
216	Dexamethasone Infusion Testing in the Diagnosis of Cushing's Syndrome. Endocrine Journal, 2005, 52, 103-109.	1.6	9

#	ARTICLE	IF	CITATIONS
217	Assessment of cardiovascular disease risk factors and diabetes mellitus in Australian prisons: is the prisoner population unhealthier than the rest of the Australian population?. Australian and New Zealand Journal of Public Health, 2005, 29, 318-323.	1.8	26
218	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. , 2005, 4, 13.		84
219	Immunome research. Immunome Research, 2005, 1, 1.	0.1	8
220	Immunoinformatics and its relevance to understanding human immune disease. Expert Review of Clinical Immunology, 2005, 1, 145-157.	3.0	50
221	The Transcriptional Landscape of the Mammalian Genome. Science, 2005, 309, 1559-1563.	12.6	3,227
222	Temporal regulation of the human immune system. Expert Review of Clinical Immunology, 2005, 1, 379-383.	3.0	5
223	The virosome concept for influenza vaccines. Vaccine, 2005, 23, S26-S38.	3.8	196
224	Information technologies for vaccine research. Expert Review of Vaccines, 2005, 4, 407-417.	4.4	21
225	A Hybrid Decision Tree " Artificial Neural Networks Ensemble Approach for Kidney Transplantation Outcomes Prediction. Lecture Notes in Computer Science, 2005, , 116-122.	1.3	4
226	A rash: Part 1. Pathology, 2004, 36, 576-579.	0.6	1
227	The perils of untimed serum cortisol measurement. Pathology, 2004, 36, 279-281.	0.6	2
228	FREP: a database of functional repeats in mouse cDNAs. Nucleic Acids Research, 2004, 32, 471D-475.	14.5	6
229	Addison's disease presenting in four adolescents with type 1 diabetes. Pediatric Diabetes, 2004, 5, 207-211.	2.9	19
230	Systematic genome-wide approach to positional candidate cloning for identification of novel human disease genes. Internal Medicine Journal, 2004, 34, 79-90.	0.8	9
231	Vaccine adjuvants: Current state and future trends. Immunology and Cell Biology, 2004, 82, 488-496.	2.3	790
232	Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunology and Cell Biology, 2004, 82, 539-546.	2.3	69
233	Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunology and Cell Biology, 2004, 82, 611-616.	2.3	95
234	Identification of "pathologs" (disease-related genes) from the RIKEN mouse cDNA dataset using human curation plus FACTS, a new biological information extraction system. BMC Genomics, 2004, 5, 28.	2.8	6

#	ARTICLE	IF	CITATIONS
235	Elevated Lymphocyte Expression of CLIP Is Associated with Type 1 Diabetes and May Be a Useful Marker of Autoimmune Susceptibility. <i>Annals of the New York Academy of Sciences</i> , 2004, 1037, 65-68.	3.8	4
236	Identification of Key β Cell Gene Signaling Pathways Involved in Type 1 Diabetes. <i>Annals of the New York Academy of Sciences</i> , 2004, 1037, 203-207.	3.8	3
237	The Power of an Integrated Informatic and Molecular Approach to Type 1 Diabetes Research. <i>Annals of the New York Academy of Sciences</i> , 2004, 1037, 216-224.	3.8	0
238	The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. , 2004, 3, 9.		77
239	Virtual models of the HLA class I antigen processing pathway. <i>Methods</i> , 2004, 34, 429-435.	3.8	25
240	Computational methods for prediction of T-cell epitopes—a framework for modelling, testing, and applications. <i>Methods</i> , 2004, 34, 436-443.	3.8	143
241	Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. <i>Vaccine</i> , 2004, 22, 1104-1113.	3.8	30
242	A swollen abdomen: Part 1. <i>Pathology</i> , 2004, 36, 193-195.	0.6	5
243	Use of Artificial Neural Networks in the Prediction of Kidney Transplant Outcomes. <i>Lecture Notes in Computer Science</i> , 2004, , 566-572.	1.3	6
244	Autoimmune Diabetes in the NOD Mouse: An Essential Role of Fas-FasL Signaling in β Cell Apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2003, 1005, 161-165.	3.8	5
245	The Role of Endoplasmic Reticulum Stress in Nonimmune Diabetes: NOD.k iHEL, a Novel Model of β Cell Death. <i>Annals of the New York Academy of Sciences</i> , 2003, 1005, 178-183.	3.8	23
246	Prevention of Autoimmune Diabetes through Immunostimulation with Q Fever Complement-Fixing Antigen. <i>Annals of the New York Academy of Sciences</i> , 2003, 1005, 423-430.	3.8	6
247	Computational tools for the study of allergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 1083-1092.	5.7	49
248	Allergen databases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 1093-1100.	5.7	63
249	Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. <i>Immunology and Cell Biology</i> , 2003, 81, 137-143.	2.3	90
250	Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. <i>Vaccine</i> , 2003, 21, 925-931.	3.8	45
251	Bioinformatics for characterisation of allergens, allergenicity and allergic crossreactivity. <i>Trends in Immunology</i> , 2003, 24, 225-228.	6.8	31
252	Influenza Virosomes in Vaccine Development. <i>Methods in Enzymology</i> , 2003, 373, 74-91.	1.0	42

#	ARTICLE	IF	CITATIONS
253	Vaccine Therapies for the Prevention of Type 1 Diabetes Mellitus. <i>Paediatric Drugs</i> , 2003, 5, 575-582.	3.1	19
254	Cytokine-Related Genes Identified From the RIKEN Full-Length Mouse cDNA Data Set. <i>Genome Research</i> , 2003, 13, 1307-1317.	5.5	2
255	Inferring Higher Functional Information for RIKEN Mouse Full-Length cDNA Clones With FACTS. <i>Genome Research</i> , 2003, 13, 1520-1533.	5.5	14
256	Mechanisms of Accelerated Immune-Mediated Diabetes Resulting from Islet β Cell Expression of a Fas Ligand Transgene. <i>Journal of Immunology</i> , 2003, 170, 4996-5002.	0.8	24
257	Identification of Novel "Pathologs" (Human Disease-Related Gene Candidates) From the RIKEN Full-Length Mouse cDNA Data Set. <i>Genome Research</i> , 2003, 13, 1559-1559.	5.5	1
258	The future for computational modelling and prediction systems in clinical immunology. <i>Novartis Foundation Symposium</i> , 2003, 254, 23-32; discussion 33-42, 98-101, 250-2.	1.1	4
259	Prospects for the Prevention and Reversal of Type 1 Diabetes Mellitus. <i>Drugs</i> , 2002, 62, 2617-2635.	10.9	12
260	Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study. <i>Molecular Medicine</i> , 2002, 8, 137-148.	4.4	133
261	Evidence from twins for acquired cellular immune hyperactivity in type 1 diabetes. <i>Immunology</i> , 2002, 106, 584-589.	4.4	9
262	Pregnancy-associated osteoporosis with hypercalcaemia. <i>Internal Medicine Journal</i> , 2002, 32, 481-485.	0.8	27
263	Prediction of promiscuous peptides that bind HLA class I molecules. <i>Immunology and Cell Biology</i> , 2002, 80, 280-285.	2.3	77
264	Computational immunology: The coming of age. <i>Immunology and Cell Biology</i> , 2002, 80, 248-254.	2.3	57
265	Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. <i>Nature</i> , 2002, 420, 563-573.	27.8	1,548
266	The Role of Fas Ligand in Beta Cell Destruction in Autoimmune Diabetes of NOD Mice. <i>Annals of the New York Academy of Sciences</i> , 2002, 958, 204-208.	3.8	34
267	Response of Serum Macrophage Migration Inhibitory Factor Levels to Stimulation or Suppression of the Hypothalamo-Pituitary-Adrenal Axis in Normal Subjects and Patients with Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1834-1840.	3.6	23
268	Methods for prediction of peptide binding to MHC molecules: a comparative study. <i>Molecular Medicine</i> , 2002, 8, 137-48.	4.4	35
269	Macrophage Migration Inhibitory Factor: A Critical Neurohumoral Mediator. , 2001, 29, 83-90.		4
270	Whole Blood Assays and the Influence of Circadian Rhythmicity on Human Cytokine Measurement. , 2001, , 163-174.		0

#	ARTICLE	IF	CITATIONS
271	Towards a unified model of neuroendocrine-immune interaction. <i>Immunology and Cell Biology</i> , 2001, 79, 350-357.	2.3	131
272	Efficient discovery of immune response targets by cyclical refinement of QSAR models of peptide binding. <i>Journal of Molecular Graphics and Modelling</i> , 2001, 19, 405-411.	2.4	35
273	Molecular immunology databases and data repositories. <i>Journal of Immunological Methods</i> , 2000, 238, 17-28.	1.4	29
274	Virosomes as an Antigen Delivery System. <i>Journal of Liposome Research</i> , 2000, 10, 329-338.	3.3	17
275	Macrophage Migration Inhibitory Factor (MIF): A Critical Neurohumoral Mediator. <i>Annals of the New York Academy of Sciences</i> , 2000, 917, 665-671.	3.8	14
276	The Chronobiology of Human Cytokine Production. <i>International Reviews of Immunology</i> , 1998, 16, 635-649.	3.3	186
277	DIURNAL RHYTHMS OF PRO-INFLAMMATORY CYTOKINES: REGULATION BY PLASMA CORTISOL AND THERAPEUTIC IMPLICATIONS. <i>Cytokine</i> , 1998, 10, 307-312.	3.2	267
278	Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. <i>Journal of Immunology</i> , 1998, 161, 617-24.	0.8	76
279	Evidence for the Viral Aetiology of IDDM. <i>Autoimmunity</i> , 1997, 25, 251-252.	2.6	6
280	HLA Class II-associated polymorphism of interferon- γ production implications for HLA-disease association. <i>Human Immunology</i> , 1997, 53, 12-16.	2.4	27
281	Danazol in the treatment of a systemic lupus erythematosus (SLE)-like illness associated with deficiency of the fourth component of complement. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 189-189.	0.5	0
282	The paradoxical association between immunodeficiency and autoimmunity: Comment on the article by Atkinson. <i>Arthritis and Rheumatism</i> , 1996, 39, 179-180.	6.7	4
283	HLA-matched control subjects are essential in studies of susceptibility to IDDM. <i>Diabetologia</i> , 1995, 38, 125-126.	6.3	12
284	Th1 and Th2: swinging to a hormonal rhythm. <i>Trends in Immunology</i> , 1995, 16, 605.	7.5	13
285	Cytokine-based human whole blood assay for the detection of antigen-reactive T cells. <i>Journal of Immunological Methods</i> , 1995, 186, 37-46.	1.4	60
286	Vaccine Adjuvants Based on Gamma Inulin. <i>Pharmaceutical Biotechnology</i> , 1995, 6, 559-580.	0.3	40
287	Difficulties and dangers of vaccination strategies for asthma and other autoimmune disorders. <i>Lancet</i> , The, 1994, 344, 1227-1228.	13.7	1
288	Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation and in vitro properties. <i>Vaccine</i> , 1991, 9, 351-357.	3.8	36

#	ARTICLE	IF	CITATIONS
289	Algammulin (gamma inulin/alum hybrid adjuvant) has greater adjuvanticity than alum for hepatitis B surface antigen in mice. Immunology Letters, 1991, 27, 131-134.	2.5	20
290	The adjuvanticity of gamma inulin. Immunology and Cell Biology, 1988, 66, 345-352.	2.3	53
291	Anti-complementary action of polymorphic solubility forms of particulate inulin. Molecular Immunology, 1986, 23, 895-901.	2.2	58
292	The anti-melanoma activity of inulin in mice. Molecular Immunology, 1986, 23, 903-908.	2.2	45
293	Complement and Cancer: Activation of the Alternative Pathway as a Theoretical Base for Immunotherapy. , 1985, 1, 125-166.		19
294	Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice. International Journal of Cancer, 1984, 33, 683-687.	5.1	12
295	Protein a treatment of cancer: Activation of a serum component with trans-species anti-B16 melanoma activity. International Journal of Cancer, 1983, 32, 737-744.	5.1	15
296	Pharmacological Management of Endocrine Conditions in the Elderly Patient. , 0, , 391-401.		1
297	Pulmonary Hypertension in Chronic Lung Diseases and/or Hypoxia. , 0, , .		1
298	Use of Artificial Neural Networks in Improving Renal Transplantation Outcomes. Graft: Organ and Cell Transplantation, 0, 5, 6-13.	0.0	4
299	ALMS1 acts as a critical molecular switch that controls Insulin-stimulated glucose transport in adipocytes. Endocrine Abstracts, 0, , .	0.0	0